Agenus Announces Positive Phase 2 Brain Cancer Vaccine Results Published in Neuro-Oncology

Agenus (NASDAQ: AGEN today announced results published from a Phase 2 study demonstrated that more than 90% of the patients treated with Prophage Series G-200 were alive